Is Traws Pharma Stock a Good Investment?
Traws Pharma Investment Advice | TRAW |
- Examine Traws Pharma's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Traws Pharma's leadership team and their track record. Good management can help Traws Pharma navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Pharmaceuticals space and any emerging trends that could impact Traws Pharma's business and its evolving consumer preferences.
- Compare Traws Pharma's performance and market position to its competitors. Analyze how Traws Pharma is positioned in terms of product offerings, innovation, and market share.
- Check if Traws Pharma pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Traws Pharma's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Traws Pharma stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Traws Pharma is a good investment.
Sell | Buy |
Cautious Hold
Market Performance | OK | Details | |
Volatility | Dangerous | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Fairly Valued | Details | |
Odds Of Distress | High | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Traws Pharma Stock
Researching Traws Pharma's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 15.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 1.67. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Traws Pharma recorded a loss per share of 5.95. The entity had not issued any dividends in recent years. The firm had 1:15 split on the 21st of May 2021.
To determine if Traws Pharma is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Traws Pharma's research are outlined below:
| Traws Pharma is way too risky over 90 days horizon | |
| Traws Pharma appears to be risky and price may revert if volatility continues | |
| Traws Pharma has high likelihood to experience some financial distress in the next 2 years | |
| Traws Pharma was previously known as ONTX Old and was traded on NASDAQ Exchange under the symbol ONTX. | |
| The company reported the previous year's revenue of 226 K. Net Loss for the year was (18.95 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Traws Pharma generates negative cash flow from operations | |
| Traws Pharma has a frail financial position based on the latest SEC disclosures | |
| About 15.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from news.google.com: Orbimed Advisors LLC Expands Stake in Traws Pharma Inc - GuruFocus.com |
Traws Pharma Quarterly Liabilities And Stockholders Equity |
|
Earnings surprises can significantly impact Traws Pharma's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Traws Pharma's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-05-15 | 2024-03-31 | -0.23 | -0.19 | 0.04 | 17 | ||
2024-03-14 | 2023-12-31 | -0.25 | -0.19 | 0.06 | 24 | ||
2023-11-15 | 2023-09-30 | -0.29 | -0.23 | 0.06 | 20 | ||
2023-08-11 | 2023-06-30 | -0.31 | -0.2 | 0.11 | 35 |
Traws Pharma's market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 8.85 M.Market Cap |
|
Traws Pharma's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.75) | (0.79) | |
| Return On Capital Employed | (1.73) | (1.65) | |
| Return On Assets | (0.75) | (0.79) | |
| Return On Equity | (2.04) | (2.14) |
Determining Traws Pharma's profitability involves analyzing its financial statements and using various financial metrics to determine if Traws Pharma is a good buy. For example, gross profit margin measures Traws Pharma's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Traws Pharma's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Traws Pharma's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Traws Pharma. Check Traws Pharma's Beneish M Score to see the likelihood of Traws Pharma's management manipulating its earnings.
Evaluate Traws Pharma's management efficiency
Traws Pharma has return on total asset (ROA) of (0.5251) % which means that it has lost $0.5251 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (10.9652) %, meaning that it created substantial loss on money invested by shareholders. Traws Pharma's management efficiency ratios could be used to measure how well Traws Pharma manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.79 in 2025. Return On Capital Employed is likely to climb to -1.65 in 2025. At this time, Traws Pharma's Total Assets are fairly stable compared to the past year. Other Current Assets is likely to climb to about 2.2 M in 2025, whereas Non Currrent Assets Other are likely to drop 855.00 in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.46 | 0.48 | |
| Tangible Book Value Per Share | 0.46 | 0.48 | |
| Enterprise Value Over EBITDA | (22.32) | (23.44) | |
| Price Book Value Ratio | 34.96 | 30.16 | |
| Enterprise Value Multiple | (22.32) | (23.44) | |
| Price Fair Value | 34.96 | 30.16 | |
| Enterprise Value | 354.3 M | 412.8 M |
Evaluating the management effectiveness of Traws Pharma allows investors to assess its financial health and operational efficiency. Coupled with an analysis of its growth prospects and the current market dynamics, we evaluate the stock's true value and future potential. Key indicators such as revenue, earnings or debt levels are examined alongside external factors like economic trends and regulatory changes. The Traws Stock analysis seeks to determine whether the stock is undervalued, appropriately priced, or overvalued, thereby guiding your investment decisions.
Beta 1.394 |
Basic technical analysis of Traws Stock
As of the 1st of February, Traws Pharma has the Risk Adjusted Performance of 0.0825, semi deviation of 7.05, and Coefficient Of Variation of 1145.47. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Traws Pharma, as well as the relationship between them. Please validate Traws Pharma mean deviation, information ratio, as well as the relationship between the Information Ratio and downside variance to decide if Traws Pharma is priced more or less accurately, providing market reflects its prevalent price of 7.17 per share. Given that Traws Pharma has jensen alpha of 1.49, we advise you to double-check Traws Pharma's current market performance to make sure the company can sustain itself at a future point.Traws Pharma's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Traws Pharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Traws Pharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Traws Pharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Understand Traws Pharma's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Traws Pharma's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0825 | |||
| Market Risk Adjusted Performance | 0.6322 | |||
| Mean Deviation | 7.36 | |||
| Semi Deviation | 7.05 | |||
| Downside Deviation | 8.24 | |||
| Coefficient Of Variation | 1145.47 | |||
| Standard Deviation | 20.0 | |||
| Variance | 399.97 | |||
| Information Ratio | 0.0823 | |||
| Jensen Alpha | 1.49 | |||
| Total Risk Alpha | (0.42) | |||
| Sortino Ratio | 0.1997 | |||
| Treynor Ratio | 0.6222 | |||
| Maximum Drawdown | 187.66 | |||
| Value At Risk | (10.41) | |||
| Potential Upside | 13.54 | |||
| Downside Variance | 67.97 | |||
| Semi Variance | 49.74 | |||
| Expected Short fall | (10.16) | |||
| Skewness | 6.39 | |||
| Kurtosis | 48.63 |
| Risk Adjusted Performance | 0.0825 | |||
| Market Risk Adjusted Performance | 0.6322 | |||
| Mean Deviation | 7.36 | |||
| Semi Deviation | 7.05 | |||
| Downside Deviation | 8.24 | |||
| Coefficient Of Variation | 1145.47 | |||
| Standard Deviation | 20.0 | |||
| Variance | 399.97 | |||
| Information Ratio | 0.0823 | |||
| Jensen Alpha | 1.49 | |||
| Total Risk Alpha | (0.42) | |||
| Sortino Ratio | 0.1997 | |||
| Treynor Ratio | 0.6222 | |||
| Maximum Drawdown | 187.66 | |||
| Value At Risk | (10.41) | |||
| Potential Upside | 13.54 | |||
| Downside Variance | 67.97 | |||
| Semi Variance | 49.74 | |||
| Expected Short fall | (10.16) | |||
| Skewness | 6.39 | |||
| Kurtosis | 48.63 |
Consider Traws Pharma's intraday indicators
Traws Pharma intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Traws Pharma stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 0.0803 | |||
| Rate Of Daily Change | 1.0 | |||
| Day Median Price | 7.3 | |||
| Day Typical Price | 7.25 | |||
| Market Facilitation Index | 0.61 | |||
| Price Action Indicator | (0.12) |
Traws Stock media impact
Far too much social signal, news, headlines, and media speculation about Traws Pharma that are available to investors today. That information is available publicly through Traws media outlets and privately through word of mouth or via Traws internal channels. However, regardless of the origin, that massive amount of Traws data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Traws Pharma news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Traws Pharma relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Traws Pharma's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Traws Pharma alpha.
Traws Pharma Corporate Management
| Robert MD | Acting Officer | Profile | |
| Mark CPA | Chief Officer | Profile | |
| Victor MD | Chief Oncology | Profile | |
| Charles Pauza | Chief Virology | Profile |
Additional Tools for Traws Stock Analysis
When running Traws Pharma's price analysis, check to measure Traws Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Traws Pharma is operating at the current time. Most of Traws Pharma's value examination focuses on studying past and present price action to predict the probability of Traws Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Traws Pharma's price. Additionally, you may evaluate how the addition of Traws Pharma to your portfolios can decrease your overall portfolio volatility.